Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

The deal with China’s Chimagen Biosciences is the latest example of pharma interest in exploring the potential of “T cell engagers” in autoimmune disease.

GlaxoSmithKline ( (GSK)) has realeased its Q3 earnings. Here is a breakdown of the information GlaxoSmithKline presented to its investors. GlaxoSmithKline (GSK) is a global biopharmaceutical ...

GlaxoSmithKline said its key brands held their market share and continued to stay in line with the respective category performance. GlaxoSmithKline Pharmaceuticals on October 29 reported a 16 ...

The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to ... I'm delighted that we've also drawn a line under the vast majority of ...

Full Year 2024 Guidance: 7% to 9% sales growth, 11% to 13% profit growth. GSK PLC (NYSE:GSK) reported a 9% sales growth and 19% profit growth year-to-date, reflecting strong performance in ...

GSK further contends that Moderna got its hands on technical know-how tied to the company’s mRNA vaccine platform by “hiring several former Novartis and GSK employees with first-hand knowledge.” ...

BRENTFORD, Britain (AP) — BRENTFORD, Britain (AP) — GSK plc (GSK) on Wednesday reported a loss of $75.4 million in its third quarter. The Brentford, Britain-based company said it had a loss of ...

Moderna to defend against GSK's claims, spokesperson says GSK seeks unspecified monetary damages from Moderna A spokesperson for Massachusetts-based Moderna said the company was aware of the ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...